Combined endoscopic and ursodeoxycholic acid treatment of biliary cast syndrome in a non-transplant patient

Panagiotis Katsinelos, Jannis Kountouras, Grigoris Chatzimavroudis, Christos Zavos, Ioannis Pilpilidis, George Paroutoglou

A 76-year-old diabetic man underwent cholecystectomy for gangrenous calculous cholecystitis. His postoperative course was complicated by the development of Candida albicans esophagitis necessitating antifungal therapy, and total parenteral nutrition (TPN) for 15 d. Seven weeks later, he presented with abdominal pain, chills and a fever of 38.5°C. On admission, clinical examination revealed right upper quadrant tenderness and jaundice. Laboratory data (normal values in parentheses) showed 7.8 mg/dL total bilirubin (< 1.2 mg/dL), 968 IU/L alkaline phosphatase (< 40 IU/L), 519 IU/L γ-glutamyl transpeptidase (< 40 IU/L), 189 IU/L ALT (< 40 IU/L), 167 IU/L AST (< 40 IU/L), 484 mg/dL cholesterol, 878 mg/dL triglyceride and 503 mg/dL cholesterol, 986 IU/L alkaline phosphatase (< 40 IU/L), 519 IU/L γ-glutamyl transpeptidase (< 40 IU/L), 189 IU/L ALT (< 40 IU/L), 167 IU/L AST (< 40 IU/L), 484 mg/dL cholesterol, 878 mg/dL triglyceride. Endoscopic retrograde cholangiopancreatography (ERCP) demonstrated extrahepatic filling defects. Despite endoscopic extraction of a biliary cast, cholestasis remained unchanged. Oral administration of ursodeoxycholic acid (UDCA), 750 mg/d, resulted in normalization of liver function tests. We, therefore, propose for the first time, combined endoscopic plus UDCA treatment for the management of biliary cast syndrome.

CASE REPORT

A 76-year-old diabetic man underwent emergent cholecystectomy for gangrenous calculous cholecystitis. He had a protracted postoperative course complicated with Candida esophagitis treated with 200 mg fluconazole, twice per day and TPN for 15 d during which dyslipidemia was present. His cholesterol level was 503 mg/dL (< 200 mg/dL) and triglyceride was 967 mg/dL (< 200 mg/dL). Seven weeks later, he presented with abdominal pain, chills and a fever of 38.5°C. On admission, clinical examination revealed right upper quadrant tenderness and jaundice. Laboratory data (normal values in parentheses) showed 7.8 mg/dL total bilirubin (< 1.2 mg/dL), 968 IU/L alkaline phosphatase (< 40 IU/L), 519 IU/L γ-glutamyl transpeptidase (< 40 IU/L), 189 IU/L ALT (< 40 IU/L), 167 IU/L AST (< 40 IU/L), 484 mg/dL cholesterol, 878 mg/dL triglyceride. Endoscopic retrograde cholangiopancreatography (ERCP) demonstrated extrahepatic filling defects. Despite endoscopic extraction of a biliary cast, cholestasis remained unchanged. Oral administration of ursodeoxycholic acid (UDCA) resulted in normalization of liver function tests.
triglycerides and 18,000 cells/mm\(^3\) white blood cell count (< 10,000 cells/mm\(^3\)).

Abdominal ultrasound and computed tomography demonstrated biliary tract dilatation without apparent lesion. At ERCP, a common bile duct tubular filling defect was found (Figure 1). Endoscopic sphincterotomy was performed, followed by basket retrieval of a cast of extrahepatic biliary tract (Figure 2). No residual cast in the visualized intrahepatic bile ducts was demonstrated. Cholangitis resolved, but cholestasis remained unchanged in the next month. UDCA (750 mg/d) was administered and a gradual improvement in cholestasis was observed with normalization of cholesstatic enzymes after a 3-mo treatment period (Figure 3). After a 6-mo treatment period, a repeated ERCP showed a normal biliary tract. The patient’s condition was excellent with normal liver function tests 6 mo after cessation of UDCA treatment when we wrote this paper.

DISCUSSION

The biliary cast syndrome describes the presence of casts causing obstruction with its resultant sequelae of biliary infection, hepatocyte damage secondary to bile stasis and ductal damage, all contributing to cholangiopathy. The diagnosis is suspected in liver-transplant patients presenting with abnormal liver-associated enzymes of a cholestatic pattern, evidence of ductal dilatation on abdominal imaging studies or clinical evidence of obstruction, such as cholangitis or jaundice\(^1\-4\) and is usually confirmed by ERCP.

To the best of our knowledge, there are only three reports of a total biliary cast in the non-transplant situation. D’Haens et al\(^5\) described an elderly lady with extensive cast formation that developed after initial recovery from emergency cholecystectomy. Despite multiple attempts at endoscopic removal, post-mortem findings confirmed the presence of diffuse bile casts and acute supplicative cholangitis. The authors suggest that, in the absence of a gallbladder, the increased bile pigment load may have initiated biliary cast formation.

In the second report, Byrne et al\(^6\) described a patient with a history of traumatic head injury requiring admission to the intensive care unit, who developed a biliary cast. Despite endoscopic and surgical attempts at cast removal from large bile ducts, liver transplantation was ultimately performed for biliary cast formation. In a recent report, Gleeson et al\(^7\) described 2 patients with biliary cast syndrome in a non liver transplant setting. In the first case, biliary cast syndrome developed in a patient with no preexisting liver pathology. But, probably hepatic infarction induced by antiphospholipid antibody syndrome triggered the ischemic event leading to extrahepatic cast formation. In the second case, the etiology of cast formation was multifactorial, including fasting-related gallbladder hypocontractility, parenteral nutrition, biliary infection and possible ischemia due to hypotension-induced sepsis.

Biochemical analysis of biliary casts in liver-transplant patients showed that bilirubin seemed to be the main component (10%-50%) of casts and comprised conjugated free and oxidized varieties. Bile acids comprised 10%-15% of the cast sample and cholesterol represented about 5%-10%\(^4\). The chemical composition of biliary casts in non-transplant patients is unknown due to its rarity. However, in both reported non-transplant patients\(^5,6\) and in our case, the biliary cast developed after difficult abdominal surgery in two patients, and severe head injury in one patient. They all had a long postoperative course with TPN. Our patient had similar characteristics (fasting, parenteral nutrition, biliary infection) with the second patient in Gleeson et al’s report\(^7\), while the underlying mechanism of biliary cast syndrome in the first patient was hepatic ischemia due...
to antiphospholipid antibody syndrome. The similarities and differences of all reported non transplant patients with biliary cast syndrome underscore its multifactorial pathogenesis. It is known that sick patients, particularly abdominal surgical and neurosurgical patients, in intensive care units have been shown to develop biliary sludge frequently and rapidly. Fasting promotes gallbladder hypocontractility due to insufficient secretion of cholecystokinin and may, in part, explain the abdominal surgical patient group preference. Other risk factors for sludge formation include TPN, pregnancy and acquired immunodeficiency syndrome.

The persistent cholestasis of our patient, despite removal of the extrahepatic biliary cast, is explained by the fact that development of cast was extensive and included the small intrahepatic ducts resulting in obstructive cholangiopathy. It is known that prolonged obstruction of the intra- and/or extrahepatic biliary tree due to stones or sludge, predisposes to caliber irregularities of the biliary system and also toxic effects of bile on hepatocytes with cholangitis further to contribute to cholestatic liver damage.

We suppose that the mechanism by which the UDCA resolved our patient’s cholestasis is the dissolution of biliary cast of small intrahepatic bile ducts because its main component is cholesterol. The presence of diabetes associated with a high level of cholesterol and combined with long-postoperative TPN contributes to hypersaturation of bile with cholesterol, and initiates biliary cast formation. Stone or sludge dissolution by UDCA is a complex physiochemical process, affecting mainly the cholesterol and phospholipid ionophase and enhancing cholesterol solubilization. It would be interesting if chromatography had been performed to reveal the components of our patient’s biliary cast and confirm our hypothesis.

The beneficial effect of UDCA on biliary cast-associated cholestatic liver damage may be related to its hepatoprotective action, improvement in biliary acid secretion and immunomodulatory properties which reduce immune-related liver damage. Mechanisms underlying the beneficial therapeutic effects of UDCA on cholestatic liver diseases include: (1) protection of injured cholangiocytes against toxic effects of bile acids, (2) stimulation of impaired biliary secretion, (3) stimulation of detoxification of hydrophobic bile acids, and (4) inhibition of apoptosis of hepatocytes. However, it is not clear which of these mechanisms by which UDCA exerts its beneficial effects on cholestatic liver diseases. Most likely, such effects depend on the specific cholestatic liver disease and its stage. Knowing that biliary infection, bile duct damage and ischemia, fasting, hemolysis and abdominal surgery are all factors that may be implicated in biliary cast syndrome, it would be interesting to use UDCA as a prophylactic in patients at risk of developing biliary cast syndrome. However, the rarity of this complication makes such a study practically impossible.

In conclusion, administration of UDCA, if cholestasis remains unchanged after endoscopic removal of extrahepatic biliary cast, is a very promising treatment modality for biliary cast syndrome.

REFERENCES

1. Starzl TE, Putnam CW, Hansbrough JF, Porter KA, Reid HA. Biliary complications after liver transplantation: with special reference to the biliary cast syndrome and techniques of secondary duct repair. Surgery 1977; 81: 212-221
2. Chen CL, Wang KL, Chuang JH, Lin JN, Chu MF, Chang CH. Biliary sludge-cast formation following liver transplantation. Hepatogastroenterology 1988; 35: 22-24
3. Tung BY, Kimmy MB. Biliary complications of obstructive liver transplantation. Dig Dis 1999; 17: 133-144
4. Shah JN, Haigh WG, Lee SP, Lucey MR, Brensinger CM, Kochman ML, Long WB, Olthoff K, Shaked A, Ginsberg GG. Biliary casts after obstructive liver transplantation: clinical factors, treatment, biochemical analysis. Am J Gastroenterol 2003; 98: 1861-1867
5. D’Haens GR, Ruchim MA, Goldberg MJ, Baker AL. Massive intra-hepatic and extra-hepatic bile cast formation after cholecystectomy. Gastroint Endosc 1993; 39: 579-581
6. Byrne MF, Chong HI, O’Donovan D, Sheehan KM, Leader MB, Kay E, McCormick PA, Broe P, Murray FE. Idiopathic cholangiopathy in a biliary cast syndrome necessitating liver transplantation following head trauma. Eur J Gastroenterol Hepatol 2003; 15: 415-417
7. Gleeson FC, Czaja AJ, Baron TH. Successful endoscopic management of biliary cast syndrome in nonliver transplant patients. J Clin Gastroenterol 2008; 42: 752-755
8. Murray FE, Stinchcombe SJ, Hawkey CJ. Development of biliary sludge in patients on intensive care unit: results of a prospective ultrasonographic study. Gut 1992; 33: 1123-1125
9. Bolondi L, Gaiani S, Testa S, Labo G. Gall bladder sludge formation during prolonged fasting after gastrointestinal tract surgery. Gut 1985; 26: 734-738
10. Horton JD, Bihlartz LE. Gallstone disease and its complications. In: Feldman M, Friedman LS, Sleisenger MH. Gastrointestinal and Liver Disease. 7th ed. Philadelphia: Saunders, 2002: 1065-1090
11. Angelico M, Della Guardia P. Review article: hepatobiliary complications associated with total parenteral nutrition. Aliment Pharmacol Ther 2000; 14 Suppl 2: 54-57
12. Tint GS, Salen G, Colalillo A, Graber D, Verga D, Speck J, Shefer S. Ursodeoxycholic acid: a safe and effective agent for dissolving cholesterol gallstones. Ann Intern Med 1982; 97: 351-356
13. Shiffman ML, Kaplan GD, Brinkman-Kaplan V, Vickers FF. Prophylaxis against gallstone formation with ursodeoxycholic acid in patients participating in a very-low-calorie diet program. Ann Intern Med 1995; 122: 899-905
14. Kowdle KV. Ursodeoxycholic acid therapy in hepatobiliary disease. Am J Med 2000; 108: 481-486
15. Hempfling W, Dilger K, Beuers U. Systematic review: ursodeoxycholic acid–adverse effects and drug interactions. Aliment Pharmacol Ther 2003; 18: 963-972
16. Paumgartner G, Beuers U. Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease. Clin Liver Dis 2004; 8: 67-81, vi
17. Parry SD, Muiesan P. Cholangiopathy and the biliary cast syndrome. Eur J Gastroenterol Hepatol 2003; 15: 341-343